New HIV drugs should be classed as inferior if they carry a higher risk of resistance
Long-acting injectable treatment highly effective in European cohort studies
Long-acting injectable version of the most popular HIV drug combination is possible
Top 5 stories on HIV in Asia from IAS 2023
Top 5 stories on HIV in Africa from IAS 2023
Injectable HIV treatment unlikely to be arriving soon in the global south
Oral lenacapavir can bridge gaps if injections must be missed
Thigh injections could be an option for long-acting cabotegravir and rilpivirine
Top 5 stories on injectable HIV treatment and PrEP from CROI 2023
